Al Fayyadh was appointed to his current role in October 2017. KFSH&RC comprises advanced specialized centers across various disciplines, including heart, neuroscience, and genomic medicine, among others. In September 2022, KFSH&RC signed an MoU with Oracle Cerner to develop joint ideas and research on data and AI. In 2022, the KFSH&RC-Madinah mega project was awarded as one of the top projects in the world in the category of large and mega projects by Project Management Institute, U.S. KFSH&RC-Riyadh is the country’s representative member and contributor to the International Cancer Genome Consortium. Al Fayyadh was previously deputy executive director of medical and clinical affairs.